GSK joins a crowd of pharma companies restricting sales under federal program
GlaxoSmithKline recently became the 14th biopharma company to switch up its approach to distributing drugs purchased via the federal 340B program for low-income individuals.
Effective April 1, GSK said it will ship products purchased at the lower, 340B prices exclusively to locations registered as a 340B covered entity or affiliate with that covered entity. This contract pharmacy policy, which will limit the number of entities that receive these reduced prices, will apply to 9 of GSK’s asthma and COPD drugs, including Advair, Ventolin, Breo, Trelegy, Anoro, Incruse, Flovent, Arnuity and Serevent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
